Cargando…

Ethics of randomised controlled trials – not yet time to give up on equipoise

In this commentary on Fries and Krishnan's argument that 'design bias' undermines the status of equipoise as the ethical justification for randomised controlled trials, it is argued that their argument is analogous to Bayesian arguments for the use of informative priors in trial desig...

Descripción completa

Detalles Bibliográficos
Autor principal: Ashcroft, Richard E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064870/
https://www.ncbi.nlm.nih.gov/pubmed/15535836
http://dx.doi.org/10.1186/ar1442
_version_ 1782123314124161024
author Ashcroft, Richard E
author_facet Ashcroft, Richard E
author_sort Ashcroft, Richard E
collection PubMed
description In this commentary on Fries and Krishnan's argument that 'design bias' undermines the status of equipoise as the ethical justification for randomised controlled trials, it is argued that their argument is analogous to Bayesian arguments for the use of informative priors in trial design, but that this does not undermine the importance of equipoise. In particular, mismatches between the outcomes of interest to industrial sponsors of research and outcomes of interest to patients and clinicians ensure that in many cases industry-sponsored trials can fail to reflect the reasonable equipoise of working clinicians.
format Text
id pubmed-1064870
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10648702005-03-12 Ethics of randomised controlled trials – not yet time to give up on equipoise Ashcroft, Richard E Arthritis Res Ther Commentary In this commentary on Fries and Krishnan's argument that 'design bias' undermines the status of equipoise as the ethical justification for randomised controlled trials, it is argued that their argument is analogous to Bayesian arguments for the use of informative priors in trial design, but that this does not undermine the importance of equipoise. In particular, mismatches between the outcomes of interest to industrial sponsors of research and outcomes of interest to patients and clinicians ensure that in many cases industry-sponsored trials can fail to reflect the reasonable equipoise of working clinicians. BioMed Central 2004 2004-09-14 /pmc/articles/PMC1064870/ /pubmed/15535836 http://dx.doi.org/10.1186/ar1442 Text en Copyright © 2004 BioMed Central Ltd
spellingShingle Commentary
Ashcroft, Richard E
Ethics of randomised controlled trials – not yet time to give up on equipoise
title Ethics of randomised controlled trials – not yet time to give up on equipoise
title_full Ethics of randomised controlled trials – not yet time to give up on equipoise
title_fullStr Ethics of randomised controlled trials – not yet time to give up on equipoise
title_full_unstemmed Ethics of randomised controlled trials – not yet time to give up on equipoise
title_short Ethics of randomised controlled trials – not yet time to give up on equipoise
title_sort ethics of randomised controlled trials – not yet time to give up on equipoise
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064870/
https://www.ncbi.nlm.nih.gov/pubmed/15535836
http://dx.doi.org/10.1186/ar1442
work_keys_str_mv AT ashcroftricharde ethicsofrandomisedcontrolledtrialsnotyettimetogiveuponequipoise